INTRODUCTION
Immune tolerance refers to unresponsiveness of the immune system toward certain substances or tissues that are normally capable of stimulating an immune response. Self-tolerance is essential for normal immune balance, and failure or breakdown of that tolerance results in autoimmunity and autoimmune diseases.
Autoimmune diseases are a group of 480 chronic, relapsing, and sometimes lethal diseases, characterized by a defective immune system resulting in the loss of tolerance to selfantigens and over-expression of autoantibodies. More importantly, autoimmune disorders often occur during reproductive years, which may lead to pregnancy loss and infertility. 1 Although great progress has been made, particularly new gene loci discoveries with the advent of genome-wide association studies, the pathogenesis of autoimmune diseases remains elusive. The origins of autoimmune diseases cannot be explained by genetic factors alone because the occurrence of autoimmune diseases in identical twins is not always consistent. 2 Subsequent studies imply that epigenetic modifications also participate in the loss of immune tolerance and autoimmunity in genetically predisposed individuals. 3 This article will review the current status of genetic and epigenetic contributions to the loss of immune tolerance in autoimmunity. Genetic and epigenetic influences on autoimmune diseases, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), type 1 diabetes (T1D) and primary biliary cirrhosis (PBC), will also be briefly discussed.
in the thymus and bone marrow for T and B lymphocytes, respectively. After T and B lymphocytes enter the peripheral tissues and lymph nodes, peripheral tolerance will occur to inhibit immune responses against the body's own tissues, which occurs primarily in the secondary lymphoid organs, such as spleens and lymph nodes. Mechanisms of peripheral tolerance include anergy (functional unresponsiveness), deletion (apoptotic cell death) and suppression by regulatory T cells. 5 As stated above, the tolerance is processed on two 'levels', in which the 'lower level' of peripheral tolerance functions as a back-up strategy of the 'upper level' of central tolerance. Autoimmune diseases may develop when self-reactive lymphocytes escape from tolerance and are thereby activated. However, the underlying exact mechanisms are not entirely known. Current knowledge suggests that autoimmunity stems from a combination of genetic variants and various acquired environmental triggers. Figure 1b illustrates the loss of tolerance and autoimmune diseases.
GENETIC INFLUENCES IN THE TOLERANCE BREAKDOWN IN AUTOIMMUNITY
The loss of tolerance is a complex process that poses a great challenge to investigate. Recent studies on monogenic forms of autoimmune diseases advance our understanding of the loss of tolerance (Table 1) 
AIRE and central tolerance
The transcription factor autoimmune regulator (AIRE) was originally identified as the mutated gene in patients with an autosomal recessive form of autoimmunity called autoimmune polyglandular syndrome Type 1 (APS1), featured by autoimmune attacks against multiple endocrine organs, skin and other tissues. 7, 8 When the gene AIRE was knocked out in mice, the thymic expression of some antigens that are normally expressed at high levels in different peripheral tissues is influenced. Therefore, T cells specific for these antigens will escape from negative selection (central tolerance), entering the periphery and initiating damage to the self. 9
Foxp3 [10] [11] [12] Correspondingly, in humans, the Foxp3 gene mutation also leads to a genetic disease called immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX syndrome), demonstrating the importance of Foxp3 in the immune system. 13
CTLA4 in T cell anergy
As an inhibitory receptor, cytotoxic T lymphocyte antigen 4 (CTLA4; CD152) is expressed by T cells and interacts with the costimulatory molecules B7-1 (CD80) and B7-2 (CD86) and is capable of inhibiting T-cell responses and promoting long-lived anergy. 14 Knockout of germline CTLA4 in mice represents a fatal syndrome with lymphocyte infiltration of multiple organs and severe enlargement of lymphoid organs. 15 Several autoimmune diseases, such as type 1 diabetes and Graves' diseases, are demonstrated to be associated with CTLA4, although the exact function has not been defined. 16 FAS and lymphocyte apoptosis Fas (CD95), the prototype of a death receptor of the tumor necrosis factor (TNF) receptor family, plays a role in the deletion of mature T and B cells that recognize self antigens. 17 The T and B lymphocytes are key players for immune responses, and during the T and B lymphocyte differentiation process, the regulation of each progression step is influenced by a potent network of transcription factors specific for each particular cellular state. Recent studies indicate that both T and B lymphocyte development are under epigenetic regulations.
DNA methylation
In naive CD4 + and CD8 + T cells, DNA hypermethylation in the promoter of IL-2 and IFN-γ was identified, suggesting that the defect in IL-2 and IFN-γ production is independent of clonal selection. 19 Similarly, CpG residues at the IL-2 promoter and enhancer are also methylated in tolerant T cells. 20 The loss of DNA methyltransferase Dnmt1 results in the overproduction of IL-2, Th1 and Th2 cytokines. 21 Loss of tolerance in autoimmunity P Zhang and Q Lu
During the process from lymphoid progenitors to the B cell lineage, transcription factors EBF and E2A contribute to the DNA demethylation and nucleosomal remodeling of the CD79a promoter, which is necessary for its transcriptional activation by Pax5 and is essential to the formation of pro-B cells. 22 Histone modifications Compared to naive T cells, when activated T cells were restimulated under anergic conditions, increased histone deacetylation was observed at the IL-2 promoter, which was associated with enhanced recruitment of HDAC1 and HDAC2. 23 Hypoacetylation at the IL-2 locus in anergic CD4 + T cells is caused by increased deacetylation and intact acetylation. The IFN-γ locus in anergic T cells is also hypoacetylated, resulting in a significant reduction of IFN-γ. 24, 25 Therefore, histone hypoacetylation at the IFN-γ and IL-2 gene loci function to sustain the closed chromatin structures and thus suppress transcriptional activities.
Unlike histone acetylation, histone methylation is more specific and complicated. For example, histone H3 trimethylation at lysine 27 (H3K27me3) is related to repressive chromatins whereas H3K4me3 is generally associated with permissive chromatins. In Th1 cells, H3K4me3 specifically marks IFN-γ and T-bet gene loci, whereas IL-4 and Gata-3 loci are imprinted with H3K27me3. 26 During the stage from the pre-pro-B cell to pro-B cell, E2A-associated genes, such as EBF and FOXO1, are modified by H3K4me, a mark of gene enhancer elements. The activation of EBF and FOXO1 will lead to histone modifications of H3K4me3 on Pax5. 27 MicroRNAs During B-cell development and differentiation, miR-181, miR--150, and miR34a help target and repress transcripts critical for genes involved in B-cell generation. Genome-wide miRNA scans during lymphopoiesis lead to the identification of miRNAs that are primed for expression at different stages of differentiation, including the repressive mark H3K27me3 associated with gene silencing of lineage-inappropriate miRNA and the presence of the epigenetically active mark H3K4me. During B cell lineage specification, miR-320, miR-191, miR-139 and miR28 act as potential regulators of B-cell progression. 28 
GENETIC AND EPIGENETIC INFLUENCES IN AUTOIMMUNE DISEASES
As stated above, both genetic and epigenetic factors play indispensable roles in the pathogenesis of autoimmune diseases, most of which have unknown etiology. Genetic background is a source of susceptibility for disease onset, but it is insufficient for disease development. Recent genome-wide association studies confirmed the strong genetic background for immune-related diseases, but they fail to illustrate the mechanisms underlying immune tolerance breakdown explained by genetic aspects alone. 29 Environmental factors, such as ultraviolet rays, infections, nutrition and chemicals, also participate in the pathogenesis of autoimmunity. 30 The advent of epigenetic research creates a bridge over genetics and the environment, providing a novel perspective to interpret these complex diseases. Tables 2 and 3 list epigenetic and genetic changes in autoimmune diseases.
Genetic and epigenetic influences on SLE SLE is a systemic, multiple-organ involved autoimmune disease with a spectrum of clinical manifestations and outcomes, characterized by the production of pathogenic autoantibodies targeting nucleic acids and their binding proteins. It is a typical model of a global loss of tolerance with the activation of autoreactive T and B cells. 31 Genetic factors of SLE. Genetic contributions to human lupus are well-established based on the fact that there is a significant difference in disease concordance between monozygotic twins (25-57%) and dizygotic twins (2-9%). 32 Chromosome 1 consists of some of the loci most consistently recognized in SLE. The linkage interval 1q23 encodes Fcγ receptors FCGR2A and FCGR3A. The variants of different affinities for IgG and its subclasses of FCGRs contribute to incomplete clearance of immune complexes, leading to deposition in the kidney and blood vessels. 33 Other disease-associated genes on chromosome 1 are PTPN22, 34 IL10 (refs 35,36) and C1Q. 37 Genes encoding the major histocompatibility complex (MHC) and components of the complement pathway (C2, C4) and TNFα and TNFβ reside in chromosome 6, and their polymorphisms have been demonstrated to be susceptible to SLE. 38, 40 Programmed cell death 1 gene (PDCD1) is upregulated in T cells, inhibiting TCR signaling and T/B cell survival. It is implicated that one intronic SNP in PDCD1 is associated with the development of SLE in Europeans. The SNP alteration on the associated allele affects the binding site for the runtrelated transcription factor 1 (RUNX1), suggesting a contribution to the development of SLE in humans. 41 CTLA4, a negative costimulatory molecule, inhibits T cell activation and may limit T cell responses under inflammation. Genetic variability in CTLA4 has also been linked to SLE development. 41, 42 Epigenetic factors of SLE. Global DNA hypomethylation in T cells is a characterized epigenetic feature in SLE, resulting in the activation of transcription and close correlations with disease activity. 43 Numerous studies have validated the critical roles of T cell DNA hypomethylation in the pathogenesis of SLE. 44, 45 Hypomethylation at specific regulatory regions of DNA is the reason for the overexpression of autoimmuneassociated genes in lupus CD4+ T cells, contributing to the pathogenesis and development of SLE. CD11a, CD40L and CD70 are well-known examples. [46] [47] [48] Lupus-associated inflammatory cytokines, such as interleukin (IL)-4 and IL-6, are epigenetically regulated by DNA demethylation. 49 During T cell activation and differentiation, DNA methylation of specific genes plays vital roles in the process. For example, Foxp3, a gene for maintaining Treg cell function, is also closely controlled by DNA methylation. 50 Additionally, transcription factors may participate in the regulation of DNA methylation. The down-regulation of RFX1 found in transcript factors screening in SLE CD4+ T cells inhibits the recruitment of DNMT1 and histone deacetylase 1 (HDAC1) to the promoter regions of CD70 and CD11a, leading to DNA hypomethylation and histone H3 hyperacetylation at these promoters. 51 Growth arrest and DNA damage-induced 45alpha (Gadd45a) functions reduce the epigenetic silencing of genes via removing methylation marks. Upregulated Gadd45a in CD4+ T cells from SLE patients promotes DNA demethylation and stimulates the expression of methylation-sensitive genes including CD70 and CD11a. 52 High mobility group box protein 1 (HMGB1) may also be involved in DNA demethylation by binding to Gadd45a. 53 Histone modification is another important epigenetic mechanism for regulating gene expression. Global hypoacetylation of histone H3 and H4 has been discovered in lupus CD4+ T cells. 54 CD70 overexpression on T cells occurs partly because of aberrant histone modifications within the TNFSF7 promoter. 55 Transcription factor cAMP-responsive element modulator (CREMα) mediates silencing of the IL2 gene in SLE T cells though the deacetylation of histone H3K18 and DNA hypermethylation. 56 In addition to T cells, significant alterations of H3K4me3 in various key candidate genes was Loss of tolerance in autoimmunity P Zhang and Q Lu observed in lupus PBMCs, 57 and altered global H4 acetylation was found in lupus monocytes. 57 miRNAs are a large group of small, non-coding RNAs that function as post-transcriptional and posttranslational regulators of gene expression by binding to the 3ʹ-untranslated region (UTR) of the mRNA of a target gene. Based on the different cell types and tissues in lupus, aberrant expression of miRNA can be observed in T cells, B cells, dendritic cells and serum. For example, increased miR-21, miR-126 and miR148a were found in SLE T cells and DNMT1 is their target, contributing to DNA hypomethylation in SLE CD4+ T cells. 58, 59 miR-142 and miR-31 are believed to regulate T cells by inhibiting IL-4, IL-10, CD40L and ICOS expression and stimulating IL-2 production, respectively. 60 A recent study on the pharmacological mechanisms of mycophenolic acid (MPA) on CD4+ T cells in SLE patients shows that miR-142 and miR-146a expression was increased after MPA activation through histone modification at the promoter region. 61 In SLE B cells, the overexpression of miR-30a is responsible for the reduction of Lyn, suggesting that miR-30a plays an important role in B cell hyperactivity. 62 Genetic and epigenetic influences on RA RA is a chronic and systemic autoimmune disease characterized by chronic inflammation and the destruction of peripheral joints. As discovered in other autoimmune diseases, such as SLE, the development of RA also requires the combination of genetic susceptibility factors and environmental influences. 63, 64 Genetic factors in RA. Genetic factors contribute to the development of at least 50% of RA patients based on the data of familial and twin studies, and the concordance rate in monozygotic twins is 12-30%. The prevalence of RA is also high in first-degree relatives. 65 HLA genes at 6p21 and HLA-DRB1 allele variants are closely associated to RA. 66 In addition to the HLA loci, many other genes related to RA have been recognized. Thanks to the development of GWAS and single- Epigenetic factors in RA. DNA methylation status in blood cells, synovium and synovial fibroblasts in RA has been investigated. Although a global hypomethylation in T cells from RA patients has been observed, there is no proof of the association between methylation levels and disease activity. 76 However, changes in DNA methylation in RA synovium and synovial fibroblasts have been reported. A genome-wide evaluation of DNA methylation loci in fibroblast-like synoviocytes (FLS) isolated from the area of the disease in RA was performed. Compared to osteoarthritis (OA), 1 859 differentially methylated loci, mostly associated with immune cell trafficking, cell adhesion, and extracellular matrix interactions, were revealed in the FLS of RA. 77 A global DNA hypomethylation in RA synovial fibroblasts has also been demonstrated. 78 Furthermore, methylation changes of a single gene also participate in the pathogenesis of RA. For example, demethylation of the IL-6 promoter in PBMCs from patients with RA results in the over-expression of IL-6, 79 which occurs in the serum, synovial tissue, and synovial fluid from patients with RA. 80 Hypomethylation of CXCL12 in RA synovial fibroblasts promotes matrix metalloproteinases and joint destruction. 81 The complexity of histone modifications gives rise to difficulties in investigating their exact mechanisms in RA, and studies were limited in the extent of the expression of histone-modifying enzymes. Conflicting data on the expression of HDACs in PBMCs and synovial tissues in RA patients were published, partly because of the diverse HDAC activities influenced by disease activity and therapy in patients enrolled in these studies. [82] [83] [84] [85] In synovial fibroblasts, increased expression of H3K4me3 in the promoters of MMP-1, MMP-3, MMP-9 and MMP-13 and decreased expression of H3K27me3 in the promoters of MMP-1 and MMP-9 were obsevered. 86 Moreover, increased histone acetylation leads to up-regulations of MMP-1 and IL-6 in synovial fibroblasts. 87, 88 These epigenetic changes provide a reasonable explanation for the over-expression of MMPs and IL-6 in RA synovial fibroblasts.
In 2008, compared to OA patients, the first screening of differentially expressed miRNAs identified overexpressed miRNA-155 and 146a in synovial fibroblasts from RA patients. 89 A recent study revealed that the target of miRNA-155 is PU.1, a transcription factor in early B cell commitment, which is downregulated during B-cell maturation. The repression of endogenous miRNA-155 levels in B cells of RA patients results in the upregulation of PU.1 and the downregulation of the antibody production. 90 Components of the toll-like receptor pathway, IRAK1 and TRAF6, are targets of miRNA-146a, but there is no difference in their levels in PBMCs from RA patients and healthy controls, 91 indicating that increased miRNA-146a alone is insufficient to restrain inflammation. Compared to OA synovial fibroblasts, miRNA--124a, which targets monocyte chemoattractant protein 1 (MCP1) and cyclin-dependent kinase 2 (CDK2), was decreased in RA, leading to decreased proliferation of synovial fibroblasts. 92 The only deregulated miRNA in the peripheral T lymphocytes of RA patients was miRNA-223, which is positively correlated with rheumatoid factor (RF) titers. 93 Furthermore, increased miRNA-223 levels suppressed the insulin-like growth factor 1 receptor (IGF-1R)-mediated IL-10 production in T cells from RA patients. 94 Genetic and epigenetic influences on T1D T1D is an autoimmune disease resulting from T cell-mediated β cell destruction in genetically susceptible individuals with involvement of both genetic and environ-mental factors. 95 Genetic factors in T1D. T1D is one of the most common heritable diseases, although a positive family history of T1D is confirmed in only 10 to 15% of newly diagnosed patients. To date, more than 50 susceptibility regions have been recognized to be linked with T1D. In T1D, the HLA class II alleles (primarily the HLA-DRB1, HLA-DQA1 and HLA-DQB1 loci) are the main susceptibility genes, and up to 50% of them have genetic risks. 96 HLA-DRB1 and DQB1 are consistently associated with T1D in almost all ethnic groups. 97 In addition to HLA class II, HLA class I genes have also been considered to be strongly associated with T1D. Among HLA class I genes, the HLA-B*39 allele, which significantly increases the risk of T1D, has one of the strongest associations with T1D. 95 Moreover, multiple non-HLA loci also contribute to disease risks, such as CTLA4, 98 PTPN22, 99 IL2RA, 100 CLEC16A, 100 PTPN2 (ref. 99) and STAT4. [101] [102] [103] Epigenetic factors in T1D. Compared to healthy controls, the global DNA methylation level is significantly increased in CD4 + T cells in patients with latent autoimmune diabetes of adults (LADA), accompanied by the upregulated expression level of DNMT3b. 104 The DNA methylation level of nineteen CpG sites correlated with the time of onset of nephropathy were identified in a genome-wide DNA methylation analysis of T1D patients with diabetic nephropathy, and one of the CpG sites located nearby gene UNC13B has been indicated to reflect a risk of diabetic nephropathy in T1D. 105 Studies have revealed that HDAC expression was aberrant in T1D patients. Decreases in H3K9Ac at the upstream promoter regions of HLA-DRB1 and an increase in H3K9Ac at the upstream promoter/enhancer region of HLA-DQB1 were noted in patients with T1D and healthy controls, and both genes are highly associated with T1D. 106 Upregulated acetylated histone H4 levels were associated with T1D patients without vascular complications, suggesting a protective role against vascular injury in T1D. 107 Genome-wide histone H3K9me2 patterns in peripheral lymphocytes and monocytes from T1D patients and normal controls were compared, presenting a significant increase in methylation levels of H3K9me2 in several high-risk genes for T1D, including the CTLA4 gene. 108 Accumulating data support a role for miRNA in the development of T1D. miR-326 was found to be significantly increased in PBMCs from patients with T1D and positively correlated with disease severity, playing important stimulatory effects toward the development of T1D by targeting important immune regulators. 109 Downregulated miR-21a and miR-93 were noticed in the PBMCs of T1D patients in the presence of incubation with glucose; however, no association with autoimmunity was observed. 110 Global miRNA profiles in PBMCs from newly diagnosed T1D patients revealed that the most downregulated miRNA, miR-146, was associated with the ongoing autoimmune imbalance in T1D. 111 Genetic and epigenetic influences on PBC PBC, which is associated with both genetic and environmental factors, is a chronic, cholestatic autoimmune liver disease and may progress to liver cirrhosis and eventually liver failure. 112, 113 Genetic factors in PBC. Growing evidence indicates that PBC is a genetic-related condition, which was supported by familial clustering, the monozygotic twin concordance and the high prevalence of other autoimmune disorders in PBC patients and their family members. 114 Similar to many other AIDs, the major genetic elements of PBC are found within the HLA region. The HLA class II DRB1*08 allele family shows the strongest association between specific HLA alleles and PBC susceptibility. 115 Other loci, such as HLA DRB1, DQB1, DPB1, DRA, and c6orf10, are also strongly related to PBC susceptibility, as implicated in a GWAS study. 116 Interestingly, specific class II HLA alleles function to protect against PBC, such as DQA1*0102, DQB1*0602, DRB1*13 and DRB1*11. 115, [117] [118] [119] Moreover, many non-HLA risk loci associated with PBC susceptibility have been discovered in high-throughput genetic studies, such as interleukin 12A (IL12A), 116 Epigenetic factors of PBC. Recently, DNA methylation profiles in 60 differentially methylated regions corresponding to 51 genes on the X chromosome and nine genes on autosomal chromosomes were identified in twins of PBC patients and normal twins. DNA hypermethylation was observed in specific gene families such as ATP12A, ATP5A1 and HOXD4, suggesting DNA methylation as a regulator in the pathogenesis of PBC. 125 A significant DNA demethylation level at the CD40L promoter is inversely correlated with IgM serum levels in CD4 + T cells from PBC patients, 126 supporting the involvement of methylation modifications of CD40L in the development of PBC. Thus far, histone modification dysregulation in PBC remains under investigation.
Dysregulated histone modifications of genes demonstrated in autoreactive T cells with PBC patients include upregulated histone H4 acetylation in the promoter regions CD40L, LIGHT, IL17 and IFNG and downregulated histone H4 acetylation in the promoter regions of TRAIL, Apo2 and HDAC7A. 127 A total of 35 independent miRNAs were found to be differentially expressed in the tissues from PBC patients, with predicted targets belonging to cell proliferation, apoptosis, inflammation, oxidative stress, and metabolism. The downregulation of microRNA-122a (miR-122a) and miR-26a and the increased expression of miR-328 and miR-299-5p were validated. 128 One example is miR26-a, contributing as a posttranscriptional regulator of the overexpression of a polycomb group protein EZH2 in PBC. 129, 130 One miRNA for a PBC target cell (cholangiocytes) is miR-506, 131 which is capable of regulating pH homeostasis by decreasing the level of InsP3R3, an intracellular Ca channel. 132 
CONCLUSION
Great progress in understanding the development and pathogenesis of AIDs has been made in recent decades, particularly with the advent of epigenetic research, which has created a bridge between genetic and environmental factors. It is believed that both genetic and epigenetic factors influence the process and development of immune tolerance on different levels. However, an exact and full picture of the network related to gene expression and epigenetic modifications on the mechanisms of loss of tolerance is urged to provide new perspectives on autoimmunity.
